Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Schedules of Concentration of Risk, by Risk Factor

For each significant customer, revenue as a percentage of revenue and accounts receivable as a percentage of accounts receivable are as follows:

	Revenue				Accounts Receivable
	Three Months Ended March 31,				March 31, 2019		December 31, 2018
	2019		2018
	(unaudited)				(unaudited)
Customer A	*		11	%	*		*
Customer B	24	%	*		35	%	65	%
Customer C	*		13	%	*		*
Customer D	*		*		13	%	*

* less than 10%

Schedule of the Cumulative Effect on Financial Information Related to the Adoption of ACS 606

The cumulative effect of changes made to the condensed consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:

	Balance as of December 31, 2018			Adjustments Due to ASC 606		Balance as of January 1, 2019
	(in thousands)
Assets:
Accounts receivable	$	35,690		$	4,907	$	40,597
Equity:
Accumulated deficit	$	(280,799	)	$	4,907	$	(275,892	)

In accordance with ASC 606 requirements under the modified retrospective method of adoption, the disclosure of the impact of adoption on the Company's condensed consolidated statement of operations and condensed consolidated balance sheet was as follows:

	Three Months Ended March 31, 2019
	As Reported Under ASC 606			Effect of Change		Balances Without Adoption of ASC606
	(in thousands)
Revenue:
Precision oncology testing	$	28,837		$	994	$	29,831
Development services	7,818			—		7,818
	March 31, 2019
	As Reported Under ASC 606			Effect of Change		Balances Without Adoption of ASC606
	(in thousands)
Assets:
Accounts receivable	$	28,989		$	994	$	29,983
Equity:
Accumulated deficit	(303,209		)	994		(302,215		)